However, its direct inhibition with anti-CTLA-4 antibodies dramatically reduced Tregs count and induced expansion of effector CD8+ T-cells at the tumor microenvironment in colon adenocarcinoma [58], further unveiling the therapeutic potential of targeting CTLA-4 [59]. The gene discussed is CTLA4; the disease is colon adenocarcinoma.